

ATTORNEY DOCKET NO. 14114.0325U2  
APPLICATION NO. 09/674,195

Listing of Claims

1. (Currently amended) An isolated *Histoplasma capsulatum* M antigen-specific nucleic acid selected from the group consisting of comprising:

a nucleic acid having a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1;

a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific fragment of a nucleic acid having of a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1; and

an *H. capsulatum* M antigen-specific fragment of a nucleic acid having with a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

wherein the nucleic acid does not contain the nucleotide sequences  
5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:14),  
5'TATTAGCTCTAGAATTACCACGGGTATCCAAGTAGTAAGG3' (SEQ ID NO:15),  
5'CCCCGAAGGGCATTGGTTTTTTATCTAATAAATACACCCC3' (SEQ ID NO:16), or  
nucleotide sequences complementary thereto,

and wherein the nucleic acid is not a nucleic acid consisting essentially of between 10 and 100 nucleotides which is able to form a hybrid at 60°C with a nucleotide polymer having a nucleotide sequence of 5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:17),  
5'CATGCTGAAAGCCTCGACTTCG3' (SEQ ID NO:18),  
5'CAUGCUGAAAGCCUCGACUUCG3' (SEQ ID NO:19) or  
5'CGAAGUCGAGGCUUUCAGCAUG3' (SEQ ID NO:20).

2. (Original) The nucleic acid of Claim 1, wherein the nucleic acid has the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

ATTORNEY DOCKET NO. 14114.0325U2  
APPLICATION NO. 09/674,195

3. (Original) The nucleic acid of Claim 1, wherein the nucleic acid has a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

4 - 5. (Canceled)

6. (Currently amended) The *H. capsulatum* M antigen-specific nucleic acid of Claim 1, wherein the nucleic acid is an *H. capsulatum* M antigen-specific fragment of a nucleic acid ~~having a nucleotide sequence as set forth in the Sequence Listing as of~~ SEQ ID NO:1.

7. (Currently amended) The *H. capsulatum* M antigen-specific nucleic acid of Claim 1, wherein the nucleic acid is an *H. capsulatum* M antigen-specific fragment of a nucleic acid ~~having~~ with a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

8 - 9. (Canceled)

10. (Withdrawn) An isolated or recombinantly-produced antigen specific to *Histoplasma capsulatum* comprising:

a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

a fragment of a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1; or

a fragment of a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

ATTORNEY DOCKET NO. 14114.0325U2  
APPLICATION NO. 09/674,195

11. (Withdrawn) The antigen of Claim 10, wherein the antigen is a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

12. (Withdrawn) The antigen of Claim 11, wherein the antigen has an amino acid sequence as set forth in the Sequence Listing as SEQ ID NO:2.

13. (Withdrawn) The antigen of Claim 10, wherein the antigen is a fragment of a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

14. (Withdrawn) The antigen of Claim 10, wherein the antigen is a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

15. (Withdrawn) The antigen of Claim 10, wherein the antigen is a fragment of a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

16. (Currently amended) A vector comprising a an *H. capsulatum* M antigen-specific nucleic acid, wherein the nucleic acid~~[[:]]~~ has a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1~~[[:]]~~ or is an *H. capsulatum* M antigen-specific fragment of a nucleic acid ~~having of a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1; or,~~ and wherein the vector is suitable for expressing the nucleic acid.

17. (Original) The vector of Claim 16, wherein the nucleic acid has a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1.

18. (Canceled)

19. (Currently amended) The vector of Claim 16, wherein the nucleic acid is an *H. capsulatum* M antigen-specific fragment of a nucleic acid ~~having of a nucleotide sequence as set forth in the Sequence Listing as SEQ ID 1.~~

**ATTORNEY DOCKET NO. 14114.0325U2**  
**APPLICATION NO. 09/674,195**

20. (Canceled)

21. (Withdrawn) A method for detecting a previous or current *Histoplasma capsulatum* infection in a subject, comprising:

(a) contacting a fluid or tissue sample from the subject which contains antibodies with an isolated or recombinantly-produced antigen which is specific to *Histoplasma capsulatum*; and

(b) detecting the presence of binding between the antibodies and the antigen, the presence of binding indicating the presence of a previous or current *Histoplasma capsulatum* infection in a subject,

wherein the antigen is:

a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

a fragment of a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the-nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1; or

a fragment of a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing 30 as SEQ ID NO:1.

22. (Withdrawn) The method of Claim 21, wherein the antigen is a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1.

23. (Withdrawn) The method of Claim 22, wherein the antigen has an amino acid sequence as set forth in the Sequence Listing as SEQ ID NO:2.

**ATTORNEY DOCKET NO. 14114.0325U2**  
**APPLICATION NO. 09/674,195**

24. (Withdrawn) The method of Claim 21, wherein the antigen is a fragment of a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

25. (Withdrawn) The method of Claim 21, wherein the antigen is a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

26. (Withdrawn) The method of Claim 21, wherein the antigen is a fragment of a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

27. (Withdrawn) An isolated antibody produced against an antigen of Claim 10.

28. (Withdrawn) A kit for detecting a previous or current *Histoplasma capsulatum* infection in a sample comprising:

(a) an isolated nucleic acid of Claim 1, an isolated or recombinantly-produced antigen of Claim 10 or an isolated antibody of Claim 27; and

(b) instructions describing the use of the nucleic acid, antigen or antibody in the detection of a previous or current *Histoplasma capsulatum* infection.

29. (Withdrawn) The kit of Claim 28, wherein the kit contains an antigen, and the antigen is a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

30. (Withdrawn) The kit of Claim 28, wherein the kit contains an antigen, and the antigen is a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

ATTORNEY DOCKET NO. 14114.0325U2  
APPLICATION NO. 09/674,195

31. (Currently amended) A An isolated host cell for expressing a polypeptide, comprising a vector containing a nucleic acid, wherein the vector is suitable for expressing the nucleic acid, and wherein the nucleic acid:

has a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1; or  
is an *H. capsulatum* M antigen-specific fragment of a nucleic acid having of a  
~~nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1; or.~~

32. (Currently amended) The isolated host cell of claim 31, wherein the nucleic acid has a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1.

33. (Canceled)

34. (Withdrawn) A method for detecting a past exposure to the fungus *Histoplasma capsulatum* comprising:

(a) injecting intradermally in the skin of a patient an effective amount of an isolated or recombinantly-produced antigen which is specific to *Histoplasma capsulatum*; and

(b) observing the skin at the injection site at a predetermined time after injection for a presence of swelling of the skin, the presence of swelling of the skin indicating a past exposure by the patient to the fungus *Histoplasma capsulatum*,  
wherein the polypeptide is:

a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

an antigenic fragment of a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1; or

**ATTORNEY DOCKET NO. 14114.0325U2**  
**APPLICATION NO. 09/674,195**

an antigenic fragment of a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

35. (Withdrawn) The method of Claim 34, wherein the antigen is a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence as set forth in the Sequence Listing 5 as SEQ ID NO:1.

36. (Withdrawn) The method of Claim 34, wherein the antigen is an antigenic fragment of a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

37. (Withdrawn) The method of Claim 34, wherein the antigen is a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

38. (Withdrawn) The method of Claim 34, wherein the antigen is a fragment of a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

39. (Withdrawn) A vaccine for the prevention of histoplasmosis comprising:

(a) an effective amount of a nucleic acid of claim 1 or an isolated or recombinantly-produced antigen of Claim 10; and

(b) a pharmaceutically-acceptable carrier.

40. (Withdrawn) A method for detecting a current *H. capsulatum* infection in a subject suspected of having an *H. capsulatum* infection comprising:

(a) contacting a fluid or tissue sample from the subject which contains antigens with antibodies generated against an antigen which contains an epitope which is unique to *H. capsulatum*; and

ATTORNEY DOCKET NO. 14114.0325U2  
APPLICATION NO. 09/674,195

(b) detecting the presence of binding between the antigens and the antibodies, the presence of binding indicating the presence of a current *H. capsulatum* infection in the subject, wherein the antigen is:

a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

a fragment of a polypeptide encoded by a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1; or

a fragment of a polypeptide encoded by a nucleic acid which is substantially the same as a nucleic acid having a nucleotide sequence, which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1.

41. (Withdrawn) An isolated *Histoplasma Capsulatum* M antigen comprising a mature polypeptide consisting essentially of the polypeptide of SEQ ID NO:2 starting with the serine residue of amino acid position 17.

42. (Withdrawn) The isolated *Histoplasma Capsulatum* M antigen of claim 41, wherein the polypeptide is a recombinant polypeptide.

43. (Withdrawn) The isolated *Histoplasma Capsulatum* M antigen of claim 42, wherein the polypeptide is produced in a prokaryotic host.

44. (Withdrawn) The isolated *Histoplasma Capsulatum* M antigen of claim 41, wherein the protein does not contain carbohydrate moieties.

45 - 46. (Canceled)

47. (Currently amended) An isolated nucleic acid ~~comprising~~ consisting of:

a nucleic acid consisting of a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1;



**ATTORNEY DOCKET NO. 14114.0325U2**  
**APPLICATION NO. 09/674,195**

a nucleic acid consisting of a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific nucleic acid which is 90% similar to a nucleic acid consisting of a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific nucleic acid which is 90% similar to a nucleic acid consisting of a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific fragment of a nucleic acid consisting of a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific fragment of a nucleic acid consisting of a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific fragment of nucleic acid which is 90% similar to a nucleic acid consisting of a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1; or

an *H. capsulatum* M antigen-specific fragment of a nucleic acid consisting of a nucleotide sequence which is 90% similar to a nucleic acid which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

wherein the nucleic acid does not contain the nucleotide sequences  
5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:14),  
5'TATTAGCTCTAGAATTACCACGGGTATCCAAGTAGTAAGG3' (SEQ ID NO:15),  
5'CCCCGAAGGGCATTGGTTTTTTATCTAATAAATACACCCC3' (SEQ ID NO:16), or  
nucleotide sequences complementary thereto,

and wherein the nucleic acid is not a nucleic acid consisting essentially of between 10 and 100 nucleotides which is able to form a hybrid at 60°C with a nucleotide polymer consisting of a nucleotide sequence of 5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:17),  
5'CATGCTGAAAGCCTCGACTTCG3' (SEQ ID NO:18),

ATTORNEY DOCKET NO. 14114.0325U2  
APPLICATION NO. 09/674,195

5'CAUGCUGAAAGCCUCGACUUCG3' (SEQ ID NO:19) or

5'CGAAGUCGAGGCUUUCAGCAUG3' (SEQ ID NO:20).

48. (Currently amended) An isolated nucleic acid ~~comprising~~ consisting of:  
a nucleic acid consisting of a nucleotide sequence as set forth in the Sequence Listing as  
SEQ ID NO:1;

a nucleic acid consisting of a nucleotide sequence which is complementary to the  
nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific nucleic acid which is 95% similar to a nucleic acid  
consisting of a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific nucleic acid which is 95% similar to a nucleic acid  
consisting of a nucleotide sequence which is complementary to the nucleotide sequence set forth  
in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific fragment of a nucleic acid consisting of a nucleotide  
sequence as set forth in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific fragment of a nucleic acid consisting of a nucleotide  
sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as  
SEQ ID NO:1;

an *H. capsulatum* M antigen-specific fragment of nucleic acid which is 95% similar to a  
nucleic acid consisting of a nucleotide sequence as set forth in the Sequence Listing as SEQ ID  
NO:1; or

an *H. capsulatum* M antigen-specific fragment of a nucleic acid consisting of a nucleotide  
sequence which is 95% similar to a nucleic acid which is complementary to the nucleotide  
sequence set forth in the Sequence Listing as SEQ ID NO:1;

wherein the nucleic acid does not contain the nucleotide sequences  
5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:14),  
5'TATTAGCTCTAGAATTACACGGGTATCCAAGTAGTAAGG3' (SEQ ID NO:15),  
5'CCCCGAAGGGCATTGGTTTTTTATCTAATAAATACACCCC3' (SEQ ID NO:16), or

ATTORNEY DOCKET NO. 14114.032SU2  
APPLICATION NO. 09/674,195

nucleotide sequences complementary thereto,

and wherein the nucleic acid is not a nucleic acid consisting essentially of between 10 and 100 nucleotides which is able to form a hybrid at 60°C with a nucleotide polymer consisting of a nucleotide sequence of 5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:17),

5'CATGCTGAAAGCCTCGACTTCG3' (SEQ ID NO:18),

5'CAUGCUGAAAGCCUCGACUUCG3' (SEQ ID NO:19) or

5'CGAAGUCGAGGCUUUCAGCAUG3' (SEQ ID NO:20).

49. (Canceled)

50. (New) An isolated *Histoplasma capsulatum* M antigen-specific nucleic acid comprising:

a nucleic acid having a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1; or

a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

wherein the nucleic acid does not contain the nucleotide sequences

5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:14),

5'TATTAGCTCTAGAATTACCACGGGTATCCAAGTAGTAAGG3' (SEQ ID NO:15),

5'CCCCGAAGGGCATTGGTTTTTTTATCTAATAAATACACCCC3' (SEQ ID NO:16), or

nucleotide sequences complementary thereto,

and wherein the nucleic acid is not a nucleic acid consisting essentially of between 10 and 100 nucleotides which is able to form a hybrid at 60°C with a nucleotide polymer having a nucleotide sequence of 5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:17),

5'CATGCTGAAAGCCTCGACTTCG3' (SEQ ID NO:18),

5'CAUGCUGAAAGCCUCGACUUCG3' (SEQ ID NO:19) or

5'CGAAGUCGAGGCUUUCAGCAUG3' (SEQ ID NO:20).

51. (New) An isolated nucleic acid consisting of:

an *H. capsulatum* M antigen-specific fragment of a nucleic acid of SEQ ID NO:1; or

**ATTORNEY DOCKET NO. 14114.0325U2  
APPLICATION NO. 09/674,195**

an *H. capsulatum* M antigen-specific fragment of a nucleic acid of a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

wherein the nucleic acid does not contain the nucleotide sequences  
5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:14),  
5'TATTAGCTCTAGAATTACCACGGGTATCCAAGTAGTAAGG3' (SEQ ID NO:15),  
5'CCCCGAAGGGCATTGGTTTTTTTATCTAATAAATACACCCC3' (SEQ ID NO:16), or  
nucleotide sequences complementary thereto,

and wherein the nucleic acid is not a nucleic acid consisting essentially of between 10 and 100 nucleotides which is able to form a hybrid at 60°C with a nucleotide polymer having a nucleotide sequence of 5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:17),  
5'CATGCTGAAAGCCTCGACTTCG3' (SEQ ID NO:18),  
5'CAUGCUGAAAGCCUCGACUUCG3' (SEQ ID NO:19) or  
5'CGAAGUCGAGGCUUUCAGCAUG3' (SEQ ID NO:20).

52. (New) An isolated *Histoplasma capsulatum* M antigen-specific nucleic acid selected from the group consisting of:  
a nucleic acid having a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1;

a nucleic acid having a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

an *H. capsulatum* M antigen-specific fragment of a nucleic acid, the nucleic acid consisting of a nucleotide sequence as set forth in the Sequence Listing as SEQ ID NO:1; and

an *H. capsulatum* M antigen-specific fragment of a nucleic acid, the nucleic acid consisting of a nucleotide sequence which is complementary to the nucleotide sequence set forth in the Sequence Listing as SEQ ID NO:1;

wherein the nucleic acid does not contain the nucleotide sequences  
5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:14),

**ATTORNEY DOCKET NO. 14114.0325U2**  
**APPLICATION NO. 09/674,195**

5'TATTAGCTCTAGAATTACCACGGGTATCCAAGTAGTAAGG3' (SEQ ID NO:15),  
5'CCCCGAAGGGCATTGGTTTTTTATCTAATAAATACACCCC3' (SEQ ID NO:16), or  
nucleotide sequences complementary thereto,

and wherein the nucleic acid is not a nucleic acid consisting essentially of between 10 and  
100 nucleotides which is able to form a hybrid at 60°C with a nucleotide polymer having a  
nucleotide sequence of 5'CGAAGTCGAGGCTTTCAGCATG3' (SEQ ID NO:17),  
5'CATGCTGAAAGCCTCGACTTCG3' (SEQ ID NO:18),  
5'CAUGCUGAAAGCCUCGACUUCG3' (SEQ ID NO:19) or  
5'CGAAGUCGAGGCUUUCAGCAUG3' (SEQ ID NO:20).

BEST AVAILABLE COPY